At 12 months, patients combining HRT with semaglutide lost an average of 16% of their body weight, compared to 12% for those taking semaglutide alone
Self-controlled case series (SCCS) + Among semaglutide users who experience incident vulvovaginitis, candidiasis, or bleeding diagnoses, compare within-person incidence in defined risk windows after each dose escalation vs baseline periods, reducing fixed confounding
Fisher, R
What we can say: GLP-1s and GLP-1/GIP agonists clearly reduce body weight, fat mass, visceral fat, and ectopic fat
Published research describes the following mechanisms for MC1R agonists like afamelanotide: NF-kappaB suppression reduced transcription of pro-inflammatory genes Cytokine modulation decreased TNF-alpha, IL-1beta, and IL-6 production Nitric oxide regulation normalization of NO pathway signaling Adhesion molecule downregulation reduced inflammatory cell migration IL-10 upregulation increased anti-inflammatory cytokine output These effects have been demonstrated in vitro and in animal models of acute, chronic, and systemic inflammation (Catania et al., 2004)
Clinical findings revealed midface deflation, sagging skin, periorbital hollowing, and prominent forehead and glabellar lines
